Tim Cloughesy

3.3k total citations
17 papers, 758 citations indexed

About

Tim Cloughesy is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Tim Cloughesy has authored 17 papers receiving a total of 758 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Epidemiology. Recurrent topics in Tim Cloughesy's work include Glioma Diagnosis and Treatment (12 papers), Meningioma and schwannoma management (4 papers) and Radiomics and Machine Learning in Medical Imaging (3 papers). Tim Cloughesy is often cited by papers focused on Glioma Diagnosis and Treatment (12 papers), Meningioma and schwannoma management (4 papers) and Radiomics and Machine Learning in Medical Imaging (3 papers). Tim Cloughesy collaborates with scholars based in United States, Malaysia and Spain. Tim Cloughesy's co-authors include Paul S. Mischel, Ingo K. Mellinghoff, Whitney B. Pope, Susan M. Chang, Carlos J. Ledezma, Johannes Czernin, Wei Chen, Victor Sai, Michael T. Selch and Emese Filka and has published in prestigious journals such as Journal of Clinical Oncology, NeuroImage and Clinical Cancer Research.

In The Last Decade

Tim Cloughesy

17 papers receiving 744 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tim Cloughesy United States 9 431 267 191 176 142 17 758
Michael Badruddoja United States 8 387 0.9× 238 0.9× 167 0.9× 152 0.9× 160 1.1× 20 681
Debra C. LaFrankie United States 10 537 1.2× 200 0.7× 120 0.6× 201 1.1× 180 1.3× 19 701
Shannon Chang United States 14 635 1.5× 281 1.1× 196 1.0× 248 1.4× 208 1.5× 37 928
Elizabeth Cohen‐Jonathan Moyal France 17 508 1.2× 328 1.2× 306 1.6× 255 1.4× 195 1.4× 50 1.1k
Stevie Threatt United States 12 501 1.2× 198 0.7× 140 0.7× 169 1.0× 171 1.2× 37 664
Ilkcan Cokgor United States 12 404 0.9× 277 1.0× 213 1.1× 188 1.1× 106 0.7× 18 880
T. Mikkelsen United States 11 515 1.2× 270 1.0× 134 0.7× 220 1.3× 205 1.4× 21 731
Alexandra Benouaich‐Amiel France 13 612 1.4× 333 1.2× 232 1.2× 253 1.4× 234 1.6× 41 979
Kenneth Aldape United States 9 322 0.7× 286 1.1× 120 0.6× 135 0.8× 149 1.0× 21 648
Jose Carrillo United States 12 439 1.0× 176 0.7× 212 1.1× 225 1.3× 111 0.8× 41 795

Countries citing papers authored by Tim Cloughesy

Since Specialization
Citations

This map shows the geographic impact of Tim Cloughesy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Cloughesy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Cloughesy more than expected).

Fields of papers citing papers by Tim Cloughesy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Cloughesy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Cloughesy. The network helps show where Tim Cloughesy may publish in the future.

Co-authorship network of co-authors of Tim Cloughesy

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Cloughesy. A scholar is included among the top collaborators of Tim Cloughesy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Cloughesy. Tim Cloughesy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Münster, Pamela N., Monica Mita, Amit Mahipal, et al.. (2019). <p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p>. Cancer Management and Research. Volume 11. 10463–10476. 67 indexed citations
2.
Antonios, Joseph, Richard G. Everson, Horacio Soto, et al.. (2018). ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION. Neuro-Oncology. 20(suppl_6). vi10–vi10. 1 indexed citations
3.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2018). ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. 20(suppl_6). vi10–vi10. 7 indexed citations
4.
Ahluwalia, Manmeet S., Jan Drappatz, Xiaobu Ye, et al.. (2018). ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE. Neuro-Oncology. 20(suppl_6). vi15–vi15. 2 indexed citations
5.
Sulman, Erik P., Nofisat Ismaila, Terri S. Armstrong, et al.. (2017). Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology. 35(3). 361–369. 115 indexed citations
6.
Groot, John de, Yuji Piao, Hai T. Tran, et al.. (2011). Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. Clinical Cancer Research. 17(14). 4872–4881. 51 indexed citations
7.
Lai, Albert, Emese Filka, Phioanh L. Nghiemphu, et al.. (2008). Phase II Pilot Study of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. International Journal of Radiation Oncology*Biology*Physics. 71(5). 1372–1380. 137 indexed citations
8.
Butowski, Nicholas, Susan M. Chang, Larry Junck, et al.. (2008). A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of Neuro-Oncology. 91(2). 175–182. 84 indexed citations
9.
Ledezma, Carlos J., Wei Chen, Victor Sai, et al.. (2008). 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience. European Journal of Radiology. 71(2). 242–248. 88 indexed citations
10.
Mellinghoff, Ingo K., Tim Cloughesy, & Paul S. Mischel. (2007). PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research. 13(2). 378–381. 107 indexed citations
11.
Brown, Paul D., et al.. (2004). Oncodiagnosis panel: 2002. Patient's symptoms not related to the lesion seen in the MR images.. PubMed. 23(6). 1591–611. 4 indexed citations
12.
Brown, Paul D., et al.. (2004). Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma.. PubMed. 23(6). 1591–611. 1 indexed citations
13.
Brown, Paul D., et al.. (2004). Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess.. PubMed. 23(6). 1591–611. 1 indexed citations
14.
Brown, Paul D., et al.. (2004). Oncodiagnosis panel: 2002. Metastatic NSCLC.. PubMed. 23(6). 1591–611. 7 indexed citations
15.
Brown, Paul D., et al.. (2003). Oncodiagnosis Panel: 2002. Radiographics. 23(6). 1591–1611. 8 indexed citations
16.
Thompson, Paul M., et al.. (2000). Mapping tumor growth rates in patients with malignant gliomas: A test of two algorithms. NeuroImage. 11(5). S905–S905. 1 indexed citations
17.
Black, Keith L., Tim Cloughesy, Sung-Cheng Huang, et al.. (1997). Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. Journal of neurosurgery. 86(4). 603–609. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Badruddoja Breakdown of academic impact, for papers by Debra C. LaFrankie Breakdown of academic impact, for papers by Shannon Chang Breakdown of academic impact, for papers by Elizabeth Cohen‐Jonathan Moyal Breakdown of academic impact, for papers by Stevie Threatt Breakdown of academic impact, for papers by Ilkcan Cokgor Breakdown of academic impact, for papers by T. Mikkelsen Breakdown of academic impact, for papers by Alexandra Benouaich‐Amiel Breakdown of academic impact, for papers by Kenneth Aldape Breakdown of academic impact, for papers by Jose Carrillo
Rankless by CCL
2026